Jacques Pierre Moreau

The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc.

Phytomedics, Inc. discovers, develops, and manufactures botanical therapeutics using proprietary platform technologies. The company was founded in December 1996 by Ilya Raskin and is headquartered in Jamesburg, NJ.

ProteoThera, Inc. is a biotechnology company that develops drug targeting technology. It offers transformative platform, a proprietary tissue matrix-binding protein fusion technology. The firm develops therapeutics to create a new paradigm in the treatment of auto inflammatory diseases and in tissue regeneration. The company was founded by Jacques P. Moreau, Parth Patwari, and Richard T. Lee and is headquartered in MA.

Part of Ipsen SA, Biomeasure, Inc. researches, develops, and manufactures peptides and toxins for treating various conditions. The company is based in Milford, MA. The company was founded by Jacques Pierre Moreau.